Sauvanet Alain, Partensky Christian, Sastre Bernard, Gigot Jean-François, Fagniez Pierre-Louis, Tuech Jean-Jacques, Millat Bertrand, Berdah Stéphane, Dousset Bertrand, Jaeck Daniel, Le Treut Yves-Patrice, Letoublon Christian
University Departments of Digestive Surgery of Hôpital Beaujon, Clichy; Hôpital Edouard Herriot, Lyon, France.
Surgery. 2002 Nov;132(5):836-43. doi: 10.1067/msy.2002.127552.
The results of medial pancreatectomy have been previously reported anecdotally. The purpose of the study was to provide short- and long-term results of MP in a large multicenter collective series.
From 1990 to 1998, 53 patients (mean age +/- SD = 49 +/- 15 years) underwent medial pancreatectomy for primary cystic neoplasms of pancreas (n = 19), endocrine neoplasms (n = 17), intraductal papillary mucinous neoplasms (IPMN) (n = 6), fibrotic stenosis of the Wirsung's duct (n = 4), or other benign (n = 4) or malignant (n = 3) diseases. The proximal (right) pancreatic remnant was sutured (n = 53), and the distal (left) remnant was either anastomosed to a jejunal loop (n = 26), to the stomach (n = 25), or oversewn (n = 2). Medial pancreatectomy was indicated in 3 patients (6%) because of failed enucleation, in 3 (6%) to prevent worsening of preexisting diabetes, or to prevent de novo diabetes in a patient with chronic pancreatitis, and deliberately in the 47 others.
The length of the resected pancreas was 5.0+/- 2.2 cm (range, 2-15). One patient (2%) died from a pancreatic fistula and portal thrombosis. Three patients were reoperated on because of complications related to the left pancreas, which was partially or totally resected. Pancreatic fistula developed in 16 patients (30%). Mean delay for the return of oral feeding was related to the presence of a pancreatic fistula. At follow-up (median = 26 months, range, 12-131), 1 pancreatic recurrence and 1 de novo diabetes occurred in patients without IPMN. In patients with IPMN, the rates of pancreatic recurrence and diabetes were 40% (2/5), respectively.
Medial pancreatectomy effectively preserves long-term endocrine function and is associated with a low risk of local recurrence, except in patients with IPMN. However, there is a high risk (30%) of PF after medial pancreatectomy.
先前已有关于中段胰腺切除术结果的零星报道。本研究的目的是在一个大型多中心系列病例中提供中段胰腺切除术的短期和长期结果。
1990年至1998年,53例患者(平均年龄±标准差=49±15岁)因胰腺原发性囊性肿瘤(n=19)、内分泌肿瘤(n=17)、导管内乳头状黏液性肿瘤(IPMN)(n=6)、维尔松氏管纤维性狭窄(n=4)或其他良性(n=4)或恶性(n=3)疾病接受了中段胰腺切除术。胰腺近端(右侧)残端予以缝合(n=53),胰腺远端(左侧)残端要么与空肠袢吻合(n=26),要么与胃吻合(n=25),要么予以缝合包埋(n=2)。3例患者(6%)因摘除术失败而行中段胰腺切除术,3例(6%)是为防止已存在的糖尿病恶化,或防止慢性胰腺炎患者发生新发糖尿病,其余47例为有意施行。
切除胰腺的长度为5.0±2.2 cm(范围2 - 15 cm)。1例患者(2%)死于胰瘘和门静脉血栓形成。3例患者因与左胰腺相关的并发症接受再次手术,左胰腺部分或全部切除。16例患者(30%)发生胰瘘。经口进食恢复的平均延迟时间与胰瘘的存在有关。随访时(中位数=26个月,范围12 - 131个月),非IPMN患者发生1例胰腺复发和1例新发糖尿病。IPMN患者的胰腺复发率和糖尿病发生率分别为40%(2/5)。
中段胰腺切除术能有效保留长期内分泌功能,且局部复发风险低,但IPMN患者除外。然而,中段胰腺切除术后胰瘘风险较高(30%)。